Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seroquel XR in Schizophrenia and Anxiety Disorder
NCT01672554Phase 3Unknown
- Sponsor
- Corporation de Recherche en Neuropsycho Pharmacologie de Quebec
- Start
- Dec 2008
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of quetiapine in schizophrenia and anxiety disorder, sponsored by Corporation de Recherche en Neuropsycho Pharmacologie de Quebec. Primary endpoint: Hamilton Anxiety Rating Scale at month 6. Status: unknown.
02
Drugs
quetiapine
03
Conditions
schizophreniaanxiety disorder
Beyond the preview
Go deeper on NCT01672554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01672554.